Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study (Q46256397)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study |
scientific article |
Statements
1 reference
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study (English)
1 reference
Harold J Burstein
1 reference
Hope S Rugo
1 reference
Joyce O'Shaughnessy
1 reference
George Sledge
1 reference
Kimberly L Blackwell
1 reference
Anna Maria Storniolo
1 reference
Gursel Aktan
1 reference
Catherine Ellis
1 reference
Allison Florance
1 reference
Svetislava Vukelja
1 reference
Joachim Bischoff
1 reference
José Baselga
1 reference
11 June 2012
1 reference
30
1 reference
21
1 reference
2585-2592
1 reference